Investments

Marketable Debt Securities

Investments in marketable debt securities were comprised of the following (in thousands):



	October 3, 2015
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Corporate bonds	$	17,612	$	4	$	(6	)	$	17,610
U.S. Agency bonds	4,998		13		—			5,011
Commercial paper	9,993		—		—			9,993
Municipal bonds	9,209		2		(1		)	9,210
	$	41,812	$	19	$	(7	)	$	41,824



	January 3, 2015
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Corporate bonds	$	35,409	$	2	$	(36	)	$	35,375
U.S. Treasury securities	32,507		12		(23		)	32,496
U.S. Agency bonds	22,545		4		(10		)	22,539
Commercial paper	12,487		—		(1		)	12,486
Municipal bonds	11,157		2		(5		)	11,154
	$	114,105	$	20	$	(75	)	$	114,050

Maturities of marketable debt securities were as follows (in thousands):



	October 3, 2015				January 3, 2015
	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Marketable debt securities – current (due in less than one year)	$	33,231	$	33,243	$	69,607	$	69,609
Marketable debt securities – non-current (due in one to two years)	8,581		8,581		44,498		44,441
	$	41,812	$	41,824	$	114,105	$	114,050

During the three months ended October 3, 2015 and September 27, 2014, we received proceeds of $59.2 million and $14.6 million, respectively, from marketable debt securities. During the nine months ended October 3, 2015 and September 27, 2014, we received proceeds of $101.0 million and $38.1 million, respectively, from marketable debt securities.

Other Investments

We previously held a minority equity investment in one of our strategic product-development partners, BAM Labs. In September 2015, we completed the acquisition of the remaining outstanding capital stock of BAM Labs. The carrying value of our equity investment in BAM Labs prior to the acquisition was $6.0 million based on the cost method. In connection with the acquisition, our equity investment was remeasured to a fair value of $12.9 million, resulting in a $3.0 million gain net of: (i) $3.4 million of acquisition related expenses; and (ii) $0.5 million of incremental BAM Labs research and development expenses. The remeasured fair value of our equity investment was based on the fair value of BAM Labs at the acquisition date. The net gain of $3.5 million is included in general and administrative expenses and the incremental BAM Labs expenses of $0.5 million are included in research and development expenses on our condensed consolidated statements of operations for the three and nine months ended October 3, 2015. See Note 2, Acquisition of BAM Labs, Inc., for details regarding this acquisition.